Background {#Sec1}
==========

Posttraumatic stress disorder (PTSD) is a mental illness that affects susceptible individuals who have experienced, witnessed, or been confronted with an event involving actual or threatened dangers \[[@CR1]\]. Individuals affected by PTSD present symptoms that, according to the DSM-5, include four diagnostic clusters (re-experiencing, avoidance, negative cognitions and mood, and arousal) \[[@CR2]\]. At least one in nine American women meet lifetime diagnostic criteria for PTSD and women's risk of PTSD is twice that of men \[[@CR3]\]. Among women, PTSD is also more likely to be chronic and associated with greater functional impairment and distinct neurobiological profiles \[[@CR4], [@CR5]\]. Evidence suggests that women are more vulnerable than men to develop PTSD when exposed to similar traumas \[[@CR6]\].

Women's higher risk for PTSD likely arises from biologic and social/environmental factors. For example, sex differences in trauma exposure may partially explain the differential risk for PTSD. Women are more likely to be exposed to sexual violence, which has a high conditional risk of PTSD \[[@CR7]\]. Alternatively, the pattern of results from twin studies suggests that PTSD may be more heritable in women than in men \[[@CR8], [@CR9]\] and results from a recent genome-wide investigation also demonstrate higher molecular heritability in women \[[@CR10]\]. Sex hormones, particularly estradiol and progesterone, have been implicated as mediators of this risk, suggesting that their effects on biological, behavioral, and cognitive pathways augment the vulnerability to PTSD \[[@CR11]\]. A recent epigenome-wide association study supported this possible mechanism; it reported an estrogen-dependent association of *HDAC4* with fear in female mice and women with PTSD \[[@CR12]\].

Genetic data can be used to investigate this complex network of multiple factors. Polygenic risk score (PRS) analyses and Mendelian randomization (MR) studies are less biased by confounders than observational studies and can be used to investigate the predisposition to complex traits, identifying shared molecular pathways, pleiotropy, and causal relationships \[[@CR13], [@CR14]\]. Here, we used summary statistics from female-specific genome-wide association studies (GWAS) of traits that may be related to disease pathogenesis---i.e. anthropometric characteristics \[[@CR15]\], reproductive physiology and behaviors \[[@CR16]\], and educational attainment \[[@CR17]\]---to examine the mechanisms underlying women's vulnerability to PTSD. Although these traits were previously indicated as related to PTSD in women, testing a wide range of genetic correlations can provide useful etiological insights and help prioritize likely causal relationships \[[@CR18]\]. A greater understanding of the biological and external social processes involved in PTSD will help to address the critically important interplay between two important public health issues: PTSD and women's health.

Methods {#Sec2}
=======

Cohorts from the Psychiatric Genomics Consortium PTSD Workgroup {#Sec3}
---------------------------------------------------------------

The individual data from the subjects included were made available by the members of the Psychiatric Genomics Consortium PTSD Workgroup. Details regarding participants, genotyping, quality control, imputation, and ancestry assignment were reported previously \[[@CR10]\]. In the present study, we used data regarding female participants from seven cohorts: Collaborative Genetic Study of Nicotine Dependence \[[@CR19]\]; Family Study of Cocaine Dependence \[[@CR20]\]; Yale-Penn \[[@CR21]\]; Grady Trauma Project \[[@CR22]\]; Marine Resilience Study \[[@CR23]\]; Nurses' Health Study \[[@CR24]\]; and Ohio National Guard \[[@CR25]\]. Because the individuals in the GWAS that were used as sources for summary statistics for the traits of interest were of European descent, we restricted our analysis to women of that population. Quality control criteria for ancestry assignment and sex check are reported in our previous publication \[[@CR10]\]. We considered imputed genotypes to maximize a consistent SNP (Single Nucleotide Polymorphism) panel between the training and testing sets. Imputed SNPs with high imputation quality (genotype call probability ≥ 0.8), minor allele frequency ≥ 1%, missingness per marker ≤ 5%, missingness per individual ≤ 5%, and Hardy-Weinberg equilibrium *P* \> 10^--4^ were retained. After applying these quality control criteria, we retained information on 4,875,110 variants in a final sample of 3577 women (966 PTSD cases and 2611 trauma-exposed controls). To investigate the specificity of our findings for PTSD in women, we investigated a sample of 4628 men (501 PTSD cases and 4127 trauma-exposed controls) from the same cohorts of the Psychiatric Genomics Consortium PTSD Workgroup. The same quality control criteria were applied to the data from men. Principal component analysis of the final sample was conducted using PLINK 1.9 \[[@CR26]\] after linkage disequilibrium (LD) pruning (R^2^ \< 0.2).

Polygenic risk score analysis {#Sec4}
-----------------------------

We conducted cross-phenotype PRS analyses using PRSice software \[[@CR27]\] (available at <http://prsice.info/>). This method permits testing whether the polygenic components of inheritance have a substantial effect on multiple complex traits \[[@CR28]\]. For polygenic profile scoring, we used summary statistics generated from female-specific GWAS of 17 traits (Table [1](#Tab1){ref-type="table"}) conducted by the Genetic Investigation of ANthropometric Traits (GIANT) Consortium \[[@CR29]--[@CR32]\], the Reproductive Genetics (Reprogen) Consortium \[[@CR33], [@CR34]\], and the Social Science Genetic Association Consortium (SSGAC) \[[@CR35], [@CR36]\]. None of the PGC-PTSD cohorts was included in these previous GWAS and, thereby, no large overlap is expected among these samples. We considered multiple association *P* value thresholds (PT = 10^--8^, 10^--7^, 10^--6^, 10^--5^, 10^--4^, 0.001, 0.05, 0.3, 0.5) for SNP inclusion, i.e. we conducted a high-resolution analysis. The PRS were calculated after using *P* value-informed clumping with a LD cut-off of R^2^ = 0.3 within a 500-kb window, and excluding the Major Histocompatibility Complex region of the genome because of its complex LD structure. The PRS that were generated were fitted in regression models with adjustments for the top ten ancestry principal components to calculate Nagelkerke's R as the figure of merit for prediction ability. We applied false discovery rate (FDR) multiple testing correction (Q \< 0.05) to correct for the number of PRS and thresholds tested (a total of 170 tests). A gene ontology (GO) enrichment analysis was conducted based on the PRS results: the variants included in the significant PRS with direction concordant with PRS direction were considered in the enrichment analysis. Variants were mapped to the nearest genes and then the gene loci were entered into the enrichment analysis conducted using the PANTHER v11.1 Overrepresentation Test (release 20160715; Reference List: Homo Sapiens) \[[@CR37]\]. FDR correction was applied to the enrichment results to account for multiple testing. The GO enrichment results were further investigated using REVIGO \[[@CR38]\]. Specifically, GO enrichments were used to make a graph-based visualization considering an allowed similarity of 0.7, UniProt as reference database, and SimRel method as the semantic similarity measure.Table 1GWAS summary statistics used for polygenic risk scoringConsortiumTraitAbbreviationWomen NVariant NData linkGenetic Investigation of ANthropometric Traits (GIANT)Body mass indexBMI128,6982,494,584<http://portals.broadinstitute.org/collaboration/giant/index.php/GIANT_consortium_data_files>BMI (age ≤ 50 years)BMI~\<50~52,2702,407,668BMI (age ≥ 50 years)BMI~\>50~86,7312,407,629HeightHeight64,8112,748,519Hip circumferenceHIP85,9732,466,814HIP adjusted for BMIHIP~adj~84,7872,466,814Waist circumferenceWC90,5432,444,344WC adjusted for BMIWC~adj~89,7592,473,027Waist--hip ratioWHR85,4662,466,093WHR adjusted for BMIWHR~adj~84,2222,467,768WHRadj (age ≤ 50 years)WHR~adj\<50~34,5232,366,527WHRadj (age ≥ 50 years)WHR~adj\>50~56,1502,366,567Reproductive Genetics (Reprogen)Age at menarcheMenarche182,4162,441,881<http://www.reprogen.org/data_download.html>Age at menopauseMenopause69,3602,418,695Social Science Genetic Association Consortium (SSGAC)Age at first birthAFB158,8562,470,136<http://www.thessgac.org/data>Education yearsEDU122,4277,643,300Number of children ever bornNEB222,8372,471,862

Two-sample Mendelian randomization analysis {#Sec5}
-------------------------------------------

The two-sample MR analysis was conducted using the R package *MendelianRandomization* (available at <https://cran.r-project.org/web/packages/MendelianRandomization/index.html>) and the GWAS summary statistics. This is a strategy to test cause--effect associations, in which evidence on the associations of genetic variants (i.e. instrumental variable) with the risk factor (i.e. exposure) and with the outcome comes from two sources \[[@CR39]\]. We used SNPs associated with waist circumference adjusted for body mass index (BMI) (WC~adj~ P \< 10^-8^ *N* = 31), which showed the most significant correlation with PTSD in our PRS analysis (FDR Q = 0.011), as the instrumental variable. The SNP-exposure and SNP-outcome coefficients (WC~adj~ and PTSD associations, respectively) were combined using an inverse-variance-weighted approach to give an overall estimate of the causal effect. To verify the stability of the results, we compared the findings obtained from inverse-variance-weighted analysis to the results of other MR approaches, including simple median, weighted median, and MR-Egger regression. Different methods have sensitivities to different potential issues, accommodate different scenarios, and vary in their statistical efficiency. Comparing the results of different methods permits validation of the analyses. MR-Egger regression intercept was considered to test for the presence of pleiotropic effects of the SNPs on the outcome \[[@CR40]\]. Due to the lack of genome-wide significant loci for PTSD, it was not possible to apply reverse MR to test the effect of PTSD-associated alleles on WC~adj~ to confirm the direction of the causal relationship between these traits \[[@CR41]\]. However, we used a reverse PRS analysis of PTSD to predict WC~adj~ and other anthropometric traits based on GWAS summary statistics. This reverse PRS analysis was conducted using PRSice software \[[@CR27]\]. To follow up a possible "evolutionary link" between female body shape and PTSD, we tested the association of genetically determined WC~adj~ with age at first sexual intercourse (AFS) and number of sexual partners (NSP). For AFS, we used female-specific summary statistics from a recent GWAS, including women of European descent only \[[@CR42]\]. This previous GWAS was conducted considering a range of AFS, which also includes a small fraction of individuals who had their first sexual intercourse before 12 years of age. For NSP, we used UK Biobank data on a total of 58,356 unrelated women of European descent. We calculated the association of the top 31 SNPs associated with WC~adj~ (*P* \< 10^--8^) with NSP using a linear regression model. Before being entered into the analysis, NSP was adjusted for age and the top ten ancestry principal components and then normalized using appropriate Box--Cox power transformations.

Data availability {#Sec6}
-----------------

Data supporting the findings of this study are available within the article and its Additional files. GWAS Summary level data used to calculate PRS in this study were obtained from links reported in Table [1](#Tab1){ref-type="table"}.

Results {#Sec7}
=======

We used summary statistics generated from female-specific GWAS of 17 traits (Table [1](#Tab1){ref-type="table"}) to yield polygenic profile scoring and tested the association of the derived PRS with PTSD considering multiple PT and using samples from the Psychiatric Genomics Consortium PTSD Workgroup (966 PTSD cases and 2611 trauma-exposed controls). Six PRS showed correlations with PTSD that survived FDR multiple testing correction (Q \< 0.05; Table [2](#Tab2){ref-type="table"}; Additional file [1](#MOESM1){ref-type="media"}). Although LD score regression is designed to analyze large sample sizes \[[@CR18]\], using this method we nevertheless replicated the directions of five correlations and two of them survived multiple testing correction (Additional file [2](#MOESM2){ref-type="media"}). The strongest PRS result was observed for WC~adj~: women with high genetically predicted WC~adj~ have low PTSD risk (PT: 10^--8^; R = --0.079, P \< 0.001, Q = 0.011). Additional file [3](#MOESM3){ref-type="media"} shows the distribution of WC~adj~ PRS in PTSD cases and controls. The same variants included in the WC~adj~ PRS also drove four of the other associations observed: waist--hip ratio (WHR, PT = 10^--7^; R = --0.064, *P* = 0.001, Q = 0.023); WHR adjusted for BMI (WHR~adj~, PT = 10^--7^; R = --0.059, *P* = 0.001, Q = 0.030), WHRadj in women aged \< 50 years (WHR~adj\<50~, PT = 10^--6^; R = --0.076, *P* = 1.25\*10^--4^, Q = 0.011), and WHR~adj~ in women aged \> 50 years (WHR~adj\>50~, PT = 10^--8^; R = --0.065, *P* = 0.001, Q = 0.023). Additional file [4](#MOESM4){ref-type="media"} reports the strong correlations of WC~adj~ PRS with these other anthropometric traits. The association between WC~adj~ PRS and PTSD appears to be specific to women; no correlation was observed in men (Additional file [5](#MOESM5){ref-type="media"}).Table 2Top genetic correlations between PTSD and PRS testedPRSPTSNP NR*P* valueQ valueWC~adj~10^--8^31--0.0796.77 × 10^--5^0.011WHR~adj\<50~10^--6^19--0.0761.25 × 10^--4^0.011WHR~adj\>50~10^--8^19--0.0650.0010.023AFB0.364,579--0.0640.0010.023WHR10^--7^32--0.0640.0010.023WHR~adj~10^--7^51--0.0590.0030.030Menarche10^--3^15100.0490.0130.074BMI~\<50~10^--7^260.0480.0150.077HIP10^--5^940.0450.0240.108Height0.125,3690.0420.0350.144WC10^--8^200.0340.0820.266BMI~\>50~10^--5^1040.0330.0990.306BMI10^--4^3160.0320.1030.312NEB10^--6^2--0.0290.1410.386HIP~adj~0.0513,3380.0290.1470.390EDU10^--8^17--0.0210.2940.641Menopause10^--5^1630.0180.3600.686

Among the significant PRS, the finding related to Age at First Birth (AFB) PRS is the only one that appears to be independent from the WC~adj~ signal because its top correlation is due to the cumulative effects of a large number of variants (AFB top-PT = 0.3, SNP N = 64,579) and not to the effect of a small number of strongly associated loci (WC~adj~ top-PT = 10^--8^, N = 31). We observed that women with a high genetically predicted AFB have low PTSD risk (R = --0.064, *P* = 0.001, Q = 0.023). Additional file [6](#MOESM6){ref-type="media"} shows the distribution of AFB PRS in PTSD cases and controls. No association between AFB PRS and PTSD was observed in men (Additional file [7](#MOESM7){ref-type="media"}). Since this genetic overlap appear to be related to the additive effect of a large number of variants (N = 64,579), we investigated which molecular mechanisms are shared between PTSD and AFB. The GO enrichment analysis based on AFB results highlighted several potential molecular mechanisms involved (Q \< 0.05; Additional file [8](#MOESM8){ref-type="media"}, respectively). Because we observed a large number of significant GO enrichments (Q \< 0.05) related to the AFB--PTSD result (N = 40), we conducted a similarity-based network analysis among the significant GO enrichments. This analysis highlighted a GO cluster (Additional file [9](#MOESM9){ref-type="media"}) related to multiple signaling mechanisms (e.g. calcium-mediated signaling and MAPK cascade).

To investigate further the WC~adj~-PTSD genetic correlation, we applied a MR approach to assess the causative mechanisms of this association. We used an inverse-variance-weighted method to calculate an overall estimate of the causal effect considering the coefficients related to the association of these variants with PTSD and WC~adj~ (Fig. [1](#Fig1){ref-type="fig"}; Additional file [10](#MOESM10){ref-type="media"}). This analysis showed a significant association of effect sizes of WC~adj~-associated SNPs with effect sizes estimated in our PTSD sample (OR = 0.35; 95% confidence interval \[CI\] = 0.17--0.73; *P* = 0.008). This translated to a relative decrease of 64.6% (95% CI = 27.5--82.7) in the risk of PTSD per 1-SD increase in WC~adj~. This result was consistent considering multiple MR approaches (Additional file [11](#MOESM11){ref-type="media"}). Furthermore, the consistency between PRS and MR analyses confirms that there is no sample overlap that is biasing our results. Indeed, these two approaches are susceptible to biases from sample overlaps, but the bias would be in opposite directions: risk of false-positive results in PRS and risk of false-negative results in two-sample MR \[[@CR43]\]. Considering the MR-Egger regression intercept, we also observe that the markers did not show evidence of pleiotropic effects (P~pleiotropy~ = 0.979), suggesting that the association of these variants with PTSD is mediated by their effect on body shape. To investigate further the potential causal relationship between PTSD and female body shape, we tested whether the PTSD PRS correlated with WC~adj~. A causal relationship between two traits should show asymmetry in the effect sizes of associated variants \[[@CR41]\]. We observed asymmetry between PTSD and WC~adj~: PTSD-associated variants showed no effect on WCadj (*P* \> 0.10; Additional file [12](#MOESM12){ref-type="media"}) but strongly predicted BMI (*P* = 5.68\*10^--7^) and other BMI-related anthropometric traits (Additional file [13](#MOESM13){ref-type="media"}). These results support a causal relationship between WC~adj~ and PTSD. We tested whether genetically determined female body shape correlated with sexual behaviors in women using female-specific genetic information regarding AFS and NSP (Additional file [10](#MOESM10){ref-type="media"}). Considering a penalized robust MR-Egger regression, we observed associations of WC~adj~ with AFS (Beta = --0.25, SE = 0.10, *P* = 0.013; Fig. [2](#Fig2){ref-type="fig"}) and NSP (Beta = 0.16, SE = 0.04, *P* \< 0.001; Fig. [2](#Fig2){ref-type="fig"}) with significant evidence of pleiotropy in both results (P~pleiotropy~ = 0.017 and \< 0.001, respectively), suggesting that the effects of these variants on sexual behaviors could be due to multiple mechanisms.Fig. 1SNP-exposure (WCadj associations) and SNP-outcome (PTSD associations) coefficients used in the MR analysis. *Error bars* (95% CIs) are reported for each association. The *solid line* represents the inverse-variance-weighted estimate Fig. 2SNP-exposure (WCadj associations) and SNP-outcome (AFS associations, *left*; NSP associations, *right*) coefficients used in the MR analysis. *Error bars* (95% CIs) are reported for each association. The *solid line* represents the MR-Egger estimate

Discussion {#Sec8}
==========

We found associations of the genetic risk for PTSD in women with genetically determined female body shape and reproductive behaviors. These findings provide novel insight into the mechanisms that may underlie the genetic vulnerability to PTSD in women.

Our strongest result reflects an inverse relationship between genetically determined female body shape and the genetic risk for PTSD. We observed that SNPs associated with anthropometric traits related to body shape independently from BMI (i.e. WC~adj~, WHR, WHR~adj~, WHR~adj\<50~, WHR~adj\>50~) are linked to the risk for PTSD. No analogous association was present in our male cohort. Human body shape is the result of strong evolutionary pressures, including sexual selection, with evident differences in selection between women and men \[[@CR44]\]. The dissimilarities between sexes are largely due to adaptation mechanisms related to female reproductive function \[[@CR44]\]. To facilitate childbirth, the pelvis is proportionately larger in women than in men. There is also variability in fat accumulation and distribution that are related to women's need for energy to be used during pregnancy and nursing: women have a higher percentage of body fat; men accumulate fat in the abdominal region, while women accumulate fat in hips, buttocks, thighs, and the lower abdomen \[[@CR45]\]. Consistent with the presence of different regulatory mechanisms related to human body shape, GWAS from the GIANT consortium identified several loci with sex-specific effects and most of them have larger effects in women than in men \[[@CR30], [@CR32]\]. Although these sex differences and their regulatory mechanisms are well-known, to our knowledge no large study has investigated the role of genetically determined body shape in women's mental health. In our study, we observed that a genetically determined evolution-related body shape (i.e. low WC~adj~, WHR, and WHR~adj~) was associated with increased risk of PTSD. A small study reported an association between observational (i.e. phenotypically observed) WHR and PTSD concordant with our finding \[[@CR46]\]. Our data are most consistent with a causal relationship between WC~adj~ and PTSD in women. Considering MR-Egger regression intercept, we did not observe a pleiotropic effect between WC~adj~ and PTSD. Conversely, there was an asymmetry in the effect sizes of associated variants: WC~adj~-associated variants affect the risk of PTSD, but PTSD-associated variants do not affect female body shape. Previous evolutionary studies reported that body shape in women is one of the traits related to reproductive attractiveness that has been selected during human evolution \[[@CR47]\]. We note that female reproductive attractiveness, which is determined by evolutionary selection pressures, is distinct from socio-cultural norms about female attractiveness that are known to differ over time and place \[[@CR48]\]. Our data can be interpreted as supporting that specific anthropometric characteristics may be related to PTSD via their role in increasing the risk of traumatic experiences related to undesired sexual behavior. Further evidence of an apparent causal relationship between WC~adj~ and experiences related to sexual function is provided by the analysis of AFS and NSP. Genetically determined WC~adj~ is associated with AFS and NSP; this provides additional evidence of the relationship between the female body shape and behaviors related to sexual interactions. As indicated by the significant evidence of pleiotropy, the relationship between female body shape and sexual behavior is likely mediated by multiple factors, including behavioral mechanisms and physiological processes related to reproductive function. Unfortunately, we cannot investigate further the relationship between female body shape and traumatic specific experiences, such as sexual assault, because trauma type information is not currently available in the PGC PTSD dataset. We hope to be able to do it in the future. In particular, we believe that longitudinal studies that include detailed life course assessments of traumatic experience will be needed to better understand the role of female body shape in risk of sexual assault or other traumatic event exposure.

Our investigation also identified an association between AFB and PTSD: genetically predicted young maternal AFB is associated with an increase of PTSD risk. This is consistent with epidemiologic observations of an inverse association between maternal AFB and psychiatric distress: mothers giving birth in their teens have an increased risk of a lifetime behavior disorder, PTSD, or an anxiety disorder compared to women who were older at first birth \[[@CR49]\]. The AFB--PTSD correlation is due to a genome-wide genetic overlap that includes thousands of independent variants, which is different from the body shape result, which was influenced by a small number of variants. This could indicate that these two traits share some pathways involved in their predisposition. Our enrichment analysis identified several molecular processes. Among them, we observed a large GO cluster of signaling mechanisms that includes several that are known to be involved in the response to traumatic experience, such as calcium-mediated signaling and the MAPK cascade \[[@CR50], [@CR51]\]. Observational studies have reported that early trauma exposures are associated with an increased risk of teen pregnancy. In particular, childhood sexual abuse is associated with increased risk for subsequent adolescent pregnancy \[[@CR52], [@CR53]\]. In line with this scenario, we note that the AFB GWAS \[[@CR35]\] was conducted without excluding birth events from non-consensual sex. For instance, although it accounts for a small fraction of the sample investigated, some of the cohorts included in this previous analysis also included births during childhood. Accordingly, a possible explanation of the AFB--PTSD correlation is that childhood abuse and sexual victimization can contribute to AFB and PTSD, and some of the trauma-response mechanisms involved may be shared among these traits. These mechanisms appear to be different from those related to the WC~adj~ results. The relationship between AFB and PTSD seems to be due to a large genetic overlap (i.e. pleiotropy); WC~adj~ appears to be involved in a causal mechanism related to women's vulnerability to PTSD (i.e. no pleiotropy).

Conclusions {#Sec9}
===========

In summary, using a genetic approach, we found two associations with the risk of PTSD in women related to body shape and reproductive behaviors. Both mechanisms appear to be female-specific (i.e. there was no such association in men) and they suggest that sex differences in trauma type prevalence and molecular mechanisms of trauma response contribute to the greater vulnerability to PTSD observed in women. Our study demonstrates how genetic research can successfully contribute to the dissection of biological and non-biological mechanisms relevant to women's health.

Additional files
================

 {#Sec10}
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